Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

Hh-signaling pathway

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (3) Autophagy (3) Bacterial (2) Cytochrome P450 (3) Endogenous Metabolite (2) Fungal (3) Hedgehog (7) Smo (5)
By Research Areas:	Cancer (9) Infection (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: RGS Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107408

SANT 2	Hedgehog	Cancer
SANT 2 is a potent antagonist of Hh-signaling pathway. Hedgehog (Hh) signaling plays an important role in cell signaling of embryonic development and adult tissue homeostasis. SANT 2 has the potential for the research of several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers .

HY-100790

Ciliobrevin A 2 Publications Verification HPI-4	Hedgehog	Cancer
Ciliobrevin A (HPI-4) is a hedgehog (Hh) signaling pathway inhibitor with median inhibitory concentration (IC₅₀) less than 10 μM .

HY-18287A

MRT-83 hydrochloride	Smo	Cancer
MRT-83 (hydrochloride) is the potent antagonist of Smoothened (Smo) receptor. MRT-83 (hydrochloride) inhibits the Hedgehog (Hh) signaling pathway and BODIPY-cyclopamine binding to human Smo. MRT-83 (hydrochloride) has the potential for researching cancer disease .

HY-150564

SMO-IN-2	Smo Hedgehog	Cancer
SMO-IN-2 (compound 1) is a potent smoothened (SMO) inhibitor with an IC₅₀ value of 123.4 nM for hedgehog (Hh) signaling pathway. SMO-IN-2 has antiproliferative activity against human medulloblastoma cell line Daoy. Anticancer activity .

HY-150567

SMO-IN-3	Smo Hedgehog	Cancer
SMO-IN-3 (compound 12a) is a potent smoothened (SMO) inhibitor with an IC₅₀ value of 34.09 nM for hedgehog (Hh) signaling pathway. SMO-IN-3 has antiproliferative activity against human medulloblastoma cell line Daoy. Anticancer activity .

HY-12316

20(S)-Hydroxycholesterol 1 Publications Verification 20α-Hydroxycholesterol	Smo Endogenous Metabolite	Cancer
20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

HY-17514

Itraconazole Maximum Cited Publications 14 Publications Verification R51211	Fungal Hedgehog Cytochrome P450 Autophagy Antibiotic Bacterial	Infection Cancer
Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC₅₀ of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor .

HY-12316R

20(S)-Hydroxycholesterol (Standard) 20α-Hydroxycholesterol (Standard)	Smo Endogenous Metabolite	Cancer
20(S)-Hydroxycholesterol (Standard) is the analytical standard of 20(S)-Hydroxycholesterol. This product is intended for research and analytical applications. 20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

HY-17514S

Itraconazole-d5 R51211-d₅	Fungal Hedgehog Cytochrome P450 Autophagy Antibiotic	Infection Cancer
Itraconazole-d₅ is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects[1][2][3].

HY-17514S2

Itraconazole-d9 R51211-d₉	Fungal Hedgehog Bacterial Autophagy Cytochrome P450 Antibiotic
Itraconazole-d₉ is the deuterium labeled Itraconazole[1]. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[2][3][4][5].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12316

20(S)-Hydroxycholesterol 1 Publications Verification 20α-Hydroxycholesterol	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Smo Endogenous Metabolite
20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

HY-12316R

20(S)-Hydroxycholesterol (Standard) 20α-Hydroxycholesterol (Standard)	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Smo Endogenous Metabolite
20(S)-Hydroxycholesterol (Standard) is the analytical standard of 20(S)-Hydroxycholesterol. This product is intended for research and analytical applications. 20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC₅₀ of 3 μM in a gene transcription reporter assay using NIH3T3 cells .

Cat. No.	Product Name	Chemical Structure

HY-17514S

Itraconazole-d5
Itraconazole-d₅ is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects[1][2][3].

Itraconazole-d5

Itraconazole-d₅ is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects[1][2][3].

HY-17514S2

Itraconazole-d9
Itraconazole-d₉ is the deuterium labeled Itraconazole[1]. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[2][3][4][5].

Itraconazole-d9

Itraconazole-d₉ is the deuterium labeled Itraconazole[1]. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[2][3][4][5].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks